Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator
Hypertrophic cardiomyopathy (HCM) is a genetic disease associated with a risk of malignant ventricular tachyarrhythmias and sudden cardiac death (SCD). Assessment of the SCD risk is crucial for its clinical management, and there has been considerable interest in developing risk stratification strate...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2023-01-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://kjim.org/upload/pdf/kjim-2022-144.pdf |
| _version_ | 1797962599038451712 |
|---|---|
| author | Yae Min Park |
| author_facet | Yae Min Park |
| author_sort | Yae Min Park |
| collection | DOAJ |
| description | Hypertrophic cardiomyopathy (HCM) is a genetic disease associated with a risk of malignant ventricular tachyarrhythmias and sudden cardiac death (SCD). Assessment of the SCD risk is crucial for its clinical management, and there has been considerable interest in developing risk stratification strategies. An implantable cardioverter-defibrillator (ICD) is a life-saving treatment for patients with HCM who are at a high-risk of ventricular tachyarrhythmias and SCD. However, a substantial number of ICD recipients experience adverse effects arising from inappropriate device therapy and implant-related complications. This has led to numerous investigations of the risk of SCD and the indications for ICD implantation. American guidelines were recently updated to include new risk markers, including left ventricular systolic dysfunction, apical aneurysm, and extensive late gadolinium enhancement, while European guidelines recommend individualized estimated 5-year SCD risk assessment models. Studies evaluating other risk factors for SCD in patients with HCM have also been published. Drawing on recent guidelines and publications on clinical risk factors, we focus this review on updated risk assessments for SCD with ICD therapy in patients with HCM. |
| first_indexed | 2024-04-11T01:15:43Z |
| format | Article |
| id | doaj.art-e04eb30df5814840ae039a8e01d1413f |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-11T01:15:43Z |
| publishDate | 2023-01-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-e04eb30df5814840ae039a8e01d1413f2023-01-04T03:50:21ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482023-01-0138171510.3904/kjim.2022.144170745Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillatorYae Min Park0Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, KoreaHypertrophic cardiomyopathy (HCM) is a genetic disease associated with a risk of malignant ventricular tachyarrhythmias and sudden cardiac death (SCD). Assessment of the SCD risk is crucial for its clinical management, and there has been considerable interest in developing risk stratification strategies. An implantable cardioverter-defibrillator (ICD) is a life-saving treatment for patients with HCM who are at a high-risk of ventricular tachyarrhythmias and SCD. However, a substantial number of ICD recipients experience adverse effects arising from inappropriate device therapy and implant-related complications. This has led to numerous investigations of the risk of SCD and the indications for ICD implantation. American guidelines were recently updated to include new risk markers, including left ventricular systolic dysfunction, apical aneurysm, and extensive late gadolinium enhancement, while European guidelines recommend individualized estimated 5-year SCD risk assessment models. Studies evaluating other risk factors for SCD in patients with HCM have also been published. Drawing on recent guidelines and publications on clinical risk factors, we focus this review on updated risk assessments for SCD with ICD therapy in patients with HCM.http://kjim.org/upload/pdf/kjim-2022-144.pdfcardiomyopathy, hypertrophicdeath, sudden, cardiacdefibrillators, implantable |
| spellingShingle | Yae Min Park Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator The Korean Journal of Internal Medicine cardiomyopathy, hypertrophic death, sudden, cardiac defibrillators, implantable |
| title | Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator |
| title_full | Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator |
| title_fullStr | Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator |
| title_full_unstemmed | Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator |
| title_short | Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator |
| title_sort | updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter defibrillator |
| topic | cardiomyopathy, hypertrophic death, sudden, cardiac defibrillators, implantable |
| url | http://kjim.org/upload/pdf/kjim-2022-144.pdf |
| work_keys_str_mv | AT yaeminpark updatedriskassessmentsforsuddencardiacdeathinhypertrophiccardiomyopathypatientswithimplantablecardioverterdefibrillator |